Comprehensive Strength of Industrial Enterprises
in Chinese Chemical and Pharmaceutical Industry 2020
7 Production Bases Across China
Total Employees of Wanbang Biopharma
Wanbang Biopharmaceuticals Office Building
Wanbang Biopharmaceuticals (Wanbang Biopharma) is a core member enterprise of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, stock code: 600196-SH, 02196-HK). The company was established in 1981, earlier known as Xuzhou Biochemical Pharmaceutical Factory. In 1998, it was reorganized into Wanbang Biochemical Pharmaceutical; in 2001, it was changed to Wanbang Biopharmaceutical. In 2004, Wanbang joined with Fosun Pharma; and in 2017, it was upgraded to Wanbang Biopharmaceuticals (Group).
Wanbang Biopharma has established a domestic first-class R&D and manufacturing site for genetic engineering drugs for prokaryotic and eukaryotic cells. The research and development of recombinant human insulin and its analogues, recombinant human erythropoietin and other recombinant protein drugs take the leading position in China. Through equity participation, Wanbang Biopharma has established a R&D laboratory of small molecule innovative drugs in San Francisco, USA, which is also in the leading position in the field of small molecule and high-difficulty generic drugs development. The company invests about 10% of the sales revenues for new product research and development annually; it has a professional R&D team with over 300 personnel, more than 52% of whom are high-level personnel such as masters or PhDs, and apply for more than 50 national patents annually, and launch several new products into market.
Currently Wanbang Biopharma holds and controls 20 subsidiaries and has established more than 7 manufacturing sites across China. Wanbang Biopharma actively improve the quality system to international level. At present, more than 10 production lines have passed site inspection by overseas health authority and obtained certification, Among which, one sterile injectable production line has passed the EU and US FDA site inspection, and one oral solid preparation production line has passed the US FDA site inspection.
Products of Wanbang Biopharma market cover the fields of active chemical ingredients and their preparations, biochemical and biological products, traditional Chinese Medicine, etc. The company specializes in the research and development, production and sales of drugs in the treatment fields of hyperglycemia, hypertension, hyperlipidemia, hyperuricemia, and tumors. Animal source insulin, Youlitong® (Febuxostat Tablets), Yibao® (EPO), Wansuping® (Glimepiride Tablets), Keyuan® (Calcium Dobesilate Capsules), and heparin sodium has the market share among the best in China; Keyi® (Compound Aloe Capsules), Kesheng® (Xihuang Capsules), Xiaokekang Granules, and Dunye Tablets are exclusive products in China. So far, the company has more than 10 products with annual sales of over 100 million RMB.
Since the inception, Wanbang Biopharma has always adhered to good faith management, and has achieved excellent performance for 30 consecutive years of profitability and positive growth. The company has nationwide marketing network, and has established a number of self-operated marketing divisions such as prescription drugs, OTC and general products. The company also has complete marketing, business, and administrative support functions, meticulous patient education and customer service, steadily developed overseas business, rapidly grown internet business, and a marketing team with 5,000 personnel.
Wanbang always upholds the core value of “Self-improvement, Teamwork Spirit, Performance and Contribution to Society”, and actively create a corporate culture of "Army, School, Family" within the enterprise. The company vigorously introduces and cultivates talents, listens to employees' voices, pays attention to employees' demands, and provides employees with space and opportunities for learning, growth and development. It is committed to provide all staff, on the platform of Wanbang Biopharma, with a prosper career, a promising development, and prosperous income, as well as the joy of work and the warmth of home!
Wanbang Biopharma also actively takes social responsibilities, vigorously promote the construction of EHS system and continuously increase the public welfare donations (annually donate several million yuan on average). Project Bang, Wanbang Diabetes Family and Wanbang’s scholarship continue to enhance medical assistance, student grants, community care, etc., and have been highly valued from the whole society.
Chairman of Wanbang Biopharma
Secretary of the Party committee of Wanbang Biopharma 、Co Chairman、President and CEO
Chairman and CEO of Wanbang Pharma Distribution